Latest Financial Results News

Reliance Worldwide Corporation Limited reported a robust 14.8% revenue increase to US$676.5 million and a 31.8% rise in net profit after tax to US$67.2 million for H1 FY25, driven by the full contribution from its Holman Industries acquisition.

Judo Bank reported a robust first half of FY25, delivering a 33% increase in underlying profit before tax driven by strong lending growth and improved margins. The bank is advancing its regional expansion with plans for 10 new locations and 20 additional bankers in FY25.

Judo Bank has reported a robust half-year performance with a 70% jump in statutory net profit, driven by strong loan growth and improved margins, while reaffirming its FY25 profit guidance.

Judo Capital Holdings Limited reported a robust 54% increase in statutory profit before tax for the half year ended December 2024, driven by strong SME loan growth and prudent cost management, despite a slight dip in net interest margin and statutory profit after tax.

Propell Holdings Limited reported a 75% surge in revenue driven by a rapidly expanding loan book, yet losses more than doubled amid rising impairments. The company is navigating growth challenges while engaging with the ASX on potential delisting.

Morphic Ethical Equities Fund Limited reported a robust turnaround with a $2.96 million profit after tax for the half-year ended December 2024, reversing last year’s losses despite no dividends declared.

Health and Plant Protein Group Limited has dramatically reduced its half-year net loss to $43,000 following the divestment of its macadamia division, though uncertainty lingers over a significant IRS receivable in the US.

Health and Plant Protein Group Limited reported a significantly reduced net loss of $43,000 for the half-year ended December 31, 2024, compared to a $748,000 loss in the prior period, despite no operational revenue following the sale of its macadamia division.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

Simonds Group delivered a resilient $13.6 million EBITDA in 1H FY25 amid a soft residential market and announced a strategic acquisition of Dennis Family Homes to fuel future growth.

Simonds Group reported a resilient first half of FY25 with EBITDA growth despite market softness and announced a strategic acquisition to strengthen its market position.

Simonds Group reported a 5.6% revenue decline for the half year ended December 2024 but achieved a 12% rise in EBITDA, driven by higher margin projects and cost control. The company also announced a strategic acquisition to expand its footprint.